Review title and timescale

1. Review title
Give the working title of the review. This must be in English. Ideally it should state succinctly the interventions or exposures being reviewed and the associated health or social problem being addressed in the review.
Effect of SiMoTang oral liquid in functional dyspepsia: a systematic review and meta-analysis of randomized controlled trials

2. Original language title
For reviews in languages other than English, this field should be used to enter the title in the language of the review. This will be displayed together with the English language title.

3. Anticipated or actual start date
Give the date when the systematic review commenced, or is expected to commence.
03/06/2016

4. Anticipated completion date
Give the date by which the review is expected to be completed.
20/08/2016

5. Stage of review at time of this submission
Indicate the stage of progress of the review by ticking the relevant boxes. Reviews that have progressed beyond the point of completing data extraction at the time of initial registration are not eligible for inclusion in PROSPERO. This field should be updated when any amendments are made to a published record.
The review has not yet started ✗

<table>
<thead>
<tr>
<th>Review stage</th>
<th>Started</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary searches</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Piloting of the study selection process</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Formal screening of search results against eligibility criteria</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Data extraction</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Risk of bias (quality) assessment</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Data analysis</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Provide any other relevant information about the stage of the review here.

Review team details

6. Named contact
The named contact acts as the guarantor for the accuracy of the information presented in the register record.
Dr Yunxia

7. Named contact email
Enter the electronic mail address of the named contact.
huyunxia56@163.com

8. Named contact address
Enter the full postal address for the named contact.
No. 138 Qixia Xianlin Avenue District of Nanjing in Jiangsu, China

9. Named contact phone number
Enter the telephone number for the named contact, including international dialing code.
+8615861128978

10. Organisational affiliation of the review
Full title of the organisational affiliations for this review, and website address if available. This field may be completed as "None" if the review is not affiliated to any organisation.
Review team members and their organisational affiliations
Give the title, first name and last name of all members of the team working directly on the review. Give the organisational affiliations of each member of the review team.

<table>
<thead>
<tr>
<th>Title</th>
<th>First name</th>
<th>Last name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr</td>
<td>HU</td>
<td>YUNXIA</td>
<td>Nanjing University of Chinese Medicine</td>
</tr>
<tr>
<td>Dr</td>
<td>Bai</td>
<td>YU</td>
<td>Nanjing University of Chinese Medicine</td>
</tr>
<tr>
<td>Ms</td>
<td>YANG</td>
<td>HUAHUI</td>
<td>The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>Professor</td>
<td>ZHAO</td>
<td>ZHIQIANG</td>
<td>Nanjing University of Chinese Medicine</td>
</tr>
<tr>
<td>Dr</td>
<td>Yang</td>
<td>Jie</td>
<td>Liyang Hospital of Traditional Chinese Medicine, Changzhou, China</td>
</tr>
<tr>
<td>Dr</td>
<td>Hua</td>
<td>ZHIYUN</td>
<td>Zhenjiang Hospital of Traditional Chinese Medicine, Zhenjiang, China</td>
</tr>
</tbody>
</table>

Funding sources/sponsors
Give details of the individuals, organizations, groups or other legal entities who take responsibility for initiating, managing, sponsoring and/or financing the review. Any unique identification numbers assigned to the review by the individuals or bodies listed should be included.
National Natural Science Foundation of China NO.81373608

Conflicts of interest
List any conditions that could lead to actual or perceived undue influence on judgements concerning the main topic investigated in the review.
Are there any actual or potential conflicts of interest?
None known

Collaborators
Give the name, affiliation and role of any individuals or organisations who are working on the review but who are not listed as review team members.

Review methods

Review question(s)
State the question(s) to be addressed / review objectives. Please complete a separate box for each question.
To evaluate the effect of SiMoTang (SMT) on gastrointestinal symptoms, gastric function and gastric sensitivity in humans with functional dyspepsia.

To evaluate the effect of SMT on quality of life in humans with functional dyspepsia.

To evaluate the incidence of adverse events in humans treated with SMT for functional dyspepsia.

Searches
Give details of the sources to be searched, and any restrictions (e.g. language or publication period). The full search strategy is not required, but may be supplied as a link or attachment.
An electronic database search will be conducted in PUBMED (1990 to June 21, 2016), EMBASE (1980 to June 21, 2016), Cochrane Library, BMJ Clinical Evidence and International Clinical Trials Registry Platform (ICTRP) until June 21, 2016, CNKI database (1979 to June 21, 2016), Chinese Biomedical Literature database (1978 to June 21, 2016), Wanfang database (1990 to June 21, 2016), and VIP database (1989 to June 21, 2016). A free text search will be done to identify articles studying functional dyspepsia using the terms “dyspepsia, functional dyspepsia, epigastric pain syndrome, postprandial discomfort syndrome, Pi-Man, Ji-Zhi or Wei-Tong”. Additionally the subject heading “dyspepsia” will be searched. These terms will be combined with the operator AND with a free text search on “SiMoTang”. Next to an electronic database search, references of included studies will be searched. Only original articles in English and Chinese will be included.
If you have one, give the link to your search strategy here. Alternatively you can e-mail this to PROSPERO and we will store and link to it.

I give permission for this file to be made publicly available

No

In this review the condition functional dyspepsia will be studied. Functional dyspepsia is an upper abdominal syndrome, which is characterized by the international criteria of the Rome Group. Functional dyspepsia consists of bothersome postprandial fullness, early satiation, epigastric pain or epigastric burning. These symptoms should be present without evidence for a structural disease. In functional dyspepsia changes in gastric function or gastric sensitivity can be present.

Studies evaluating humans with functional dyspepsia will be eligible for inclusion. Functional dyspepsia can be defined by the Rome I, II, III or IV criteria and on clinical grounds. The presence of other gastrointestinal disorders, which could cause abdominal discomfort similar to functional dyspepsia should be ruled out.

Studies using SMT with any dosage will be considered for inclusion. The duration of the treatment should be at least 7 days.

Placebo or positive controlled studies will be included.

In this review only randomized controlled trials will be included. Crossover studies may be eligible if randomization and blinding took place and if data from separate study groups are available. Only original articles in English and Chinese will be included.

In this review only randomized controlled trials will be included. Crossover studies may be eligible if randomization and blinding took place and if data from separate study groups are available. Only original articles in English and Chinese will be included.

Give summary details of the setting and other relevant characteristics which help define the inclusion or exclusion criteria.

Give the most important outcomes.

Give information on timing and effect measures, as appropriate.

Give information on timing and effect measures, as appropriate.

Give the procedure for selecting studies for the review and extracting data, including the number of researchers involved and how discrepancies will be resolved. List the data to be extracted.
Risk of bias (quality) assessment
State whether and how risk of bias will be assessed, how the quality of individual studies will be assessed, and whether and how this will influence the planned synthesis.
Two authors will assess the risk of bias of each study individually. For this assessment the Cochrane Collaboration’s tool for assessing risk of bias will be used. Any disagreement will be discussed with a third author.

Strategy for data synthesis
Give the planned general approach to be used, for example whether the data to be used will be aggregate or at the level of individual participants, and whether a quantitative or narrative (descriptive) synthesis is planned. Where appropriate a brief outline of analytic approach should be given.
Data extracted from the studies will be presented in narrative form and in table form. Additionally when extracted data are suitable a meta-analysis will be done using a fixed-effect/random-effect model. Heterogeneity will be assessed using both chi-squared test and I-squared statistic. Indication of publication bias will be assessed and data about this will be presented using a funnel plot.

Analysis of subgroups or subsets
Give any planned exploration of subgroups or subsets within the review. ‘None planned’ is a valid response if no subgroup analyses are planned.
Dosage of SMT Duration of therapy Differences in gender or age relapse rate

Review general information

Type and method of review
Select the type of review and the review method from the drop down list.
Systematic review

Language
Select the language(s) in which the review is being written and will be made available, from the drop down list. Use the control key to select more than one language.
Chinese-Simplified

Will a summary/abstract be made available in English?
Yes

Country
Select the country in which the review is being carried out from the drop down list. For multi-national collaborations select all the countries involved. Use the control key to select more than one country.
China

Other registration details
Give the name of any organisation where the systematic review title or protocol is registered together with any unique identification number assigned. If extracted data will be stored and made available through a repository such as the Systematic Review Data Repository (SRDR), details and a link should be included here.

Reference and/or URL for published protocol
Give the citation for the published protocol, if there is one.
Give the link to the published protocol, if there is one. This may be to an external site or to a protocol deposited with CRD in pdf format.

I give permission for this file to be made publicly available
No

Dissemination plans
Give brief details of plans for communicating essential messages from the review to the appropriate audiences.
Do you intend to publish the review on completion?
Yes

Keywords
Give words or phrases that best describe the review. (One word per box, create a new box for each term)
37  Details of any existing review of the same topic by the same authors
    Give details of earlier versions of the systematic review if an update of an existing review is being registered,
    including full bibliographic reference if possible.

38  Current review status
    Review status should be updated when the review is completed and when it is published.
    **Ongoing**

39  Any additional information
    Provide any further information the review team consider relevant to the registration of the review.

40  Details of final report/publication(s)
    This field should be left empty until details of the completed review are available.
    Give the full citation for the final report or publication of the systematic review.
    Give the URL where available.